Both PD-1 inhibitors independently developed by Chinese pharma companies had been approved by the FDA. In addition, BeiGene’s zanubrutinib (Brukinsa) received conditional approval from the NMPA ...

Similarly, 62% and 60%, respectively, said they trust health information provided by the National Institute of Health (NIH) and the Food and Drug Administration (FDA). Forty-five percent said they ...

including the FDA, EMA, and NMPA. "This milestone towards MPA qualification reflects the continued dedication of our team to set a new standard in testing antibody drug specificity. Our continued ...

The China National Medical Products Administration (NMPA) has granted expanded approval to MSD's GARDASIL, [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for use ...

PARP1 selective inhibitor IMP1734 has obtained IND clearance from FDA and NMPA, as well as completed FPI in early 2024.

In addition, in June 2024, IBI343 was granted Fast Track Designation by the US Food and Drug Administration (FDA) for the treatment of advanced ... including gastric cancer.” NMPA Breakthrough Therapy ...

On February 2, 2025, Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics ... China’s National Medical Products Administration (NMPA) previously accepted ...

IceCure Medical has submitted a regulatory filing to China's National Medical Products Administration (NMPA) seeking the approval of its ProSense cryoablation system, which is designed for ...

In 2023, Sunvozertinib was granted accelerated approval by the National Medical Products Administration (NMPA) of China, making it the world's first and only oral treatment for NSCLC patients with ...